Vivoryon Therapeutics NV (AS:VVY) — Stock Price
Vivoryon Therapeutics NV (AS:VVY) is currently trading at €1.15 EUR, down 6.50% today. Over the past 52 weeks, shares have ranged between €1.00 and €1.72. This page tracks Vivoryon Therapeutics NV's live share price on the AS exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see VVY market cap.
Vivoryon Therapeutics NV (VVY) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Vivoryon Therapeutics NV's daily closing share price and trading volume on the AS exchange over the past year, giving a clear view of recent price momentum and liquidity.
Vivoryon Therapeutics NV Income Statement — Revenue, Profit & Earnings by Year
Vivoryon Therapeutics NV's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €0.00 | €0.00 | €-3.62 Million | €0.00 | €10.76 Million |
| Cost of Revenue | €147.00K | €147.00K | €-525.00K | €161.00K | €1.73 Million |
| Gross Profit | €-147.00K | €-147.00K | €-3.10 Million | €-161.00K | €9.03 Million |
| Research & Development | €4.38 Million | €14.06 Million | €17.64 Million | €20.22 Million | €17.45 Million |
| SG&A | €4.80 Million | €6.90 Million | €3.27 Million | €8.90 Million | €4.55K |
| Total Operating Expenses | €9.03 Million | €20.81 Million | €25.74 Million | €28.97 Million | €21.84 Million |
| Operating Income | €-9.18 Million | €-20.96 Million | €-28.84 Million | €-29.13 Million | €-12.81 Million |
| EBITDA | €-9.03 Million | €-20.34 Million | €-28.35 Million | €-28.17 Million | €-12.03 Million |
| EBIT | €-9.18 Million | €-20.48 Million | €-28.52 Million | €-28.33 Million | €-12.20 Million |
| Interest Expense | €45.00K | €86.00K | €56.00K | €24.00K | €24.00K |
| Income Before Tax | €-8.85 Million | €-20.57 Million | €-28.58 Million | €-28.36 Million | €-12.22 Million |
| Income Tax Expense | — | — | €-234.00K | €-199.00K | €432.00K |
| Net Income | €-8.85 Million | €-20.57 Million | €-28.34 Million | €-28.16 Million | €-12.65 Million |
Vivoryon Therapeutics NV Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Vivoryon Therapeutics NV's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €7.52 Million | €11.28 Million | €30.83 Million | €31.38 Million | €24.52 Million |
| Total Current Assets | €6.43 Million | €10.07 Million | €29.81 Million | €30.69 Million | €20.23 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | €33.00K | €21.00K | €10.02 Million | €7.00K | €7.00K |
| Net Receivables | €142.00K | €312.00K | €495.00K | €3.96 Million | €3.36 Million |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | — | €176.00K | €285.00K |
| Goodwill | — | — | — | — | — |
| Total Liabilities | €2.79 Million | €3.40 Million | €4.55 Million | €4.87 Million | €7.96 Million |
| Total Current Liabilities | €837.00K | €1.40 Million | €3.18 Million | €3.27 Million | €5.05 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | €-5.51 Million | €-9.26 Million | €-18.52 Million | €-26.42 Million | €-14.44 Million |
| Total Stockholder Equity | €4.73 Million | €7.88 Million | €26.28 Million | €26.51 Million | €16.56 Million |
| Retained Earnings | €-178.22 Million | €-169.37 Million | €-148.80 Million | €-120.46 Million | €-92.30 Million |
Vivoryon Therapeutics NV Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Vivoryon Therapeutics NV generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €-8.46 Million | €-19.17 Million | €-21.54 Million | €-21.79 Million | €-11.26 Million |
| Capital Expenditures | €6.00K | €2.00K | €514.00K | €13.00K | €28.00K |
| Free Cash Flow | €-8.46 Million | €-19.18 Million | €-22.05 Million | €-21.81 Million | €-11.29 Million |
| Investing Cash Flow | €-6.00K | €10.00 Million | €-10.51 Million | €-13.00K | €-28.00K |
| Financing Cash Flow | €4.71 Million | €-57.00K | €24.16 Million | €33.38 Million | €-827.00K |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | €893.00K | €2.18 Million | €3.94 Million | €3.49 Million | €1.76 Million |
| Depreciation | €147.00K | €147.00K | €167.00K | €161.00K | €165.00K |
| Change in Cash | €-3.75 Million | €-9.20 Million | €-7.99 Million | €11.89 Million | €-11.64 Million |
Vivoryon Therapeutics NV Earnings History — EPS Actual vs. Analyst Estimates
Track Vivoryon Therapeutics NV's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Jun 16, 2026 | — | — | — |
| Dec 04, 2025 | 0.00 | 0.00 | — |
| Sep 04, 2025 | -0.21 | -0.79 | +73.42% |
| Apr 29, 2025 | 0.00 | -0.49 | +100.00% |
| Dec 10, 2024 | 0.00 | 0.00 | — |
| Sep 12, 2024 | -0.52 | -0.63 | +17.46% |
| Apr 24, 2024 | -0.52 | -0.52 | +0.00% |
| Jan 08, 2024 | 0.00 | -0.52 | +100.00% |